Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Drops By 8.9%

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the recipient of a large decrease in short interest in September. As of September 30th, there was short interest totalling 54,200 shares, a decrease of 8.9% from the September 15th total of 59,500 shares. Approximately 0.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 17,700 shares, the days-to-cover ratio is presently 3.1 days.

Avalo Therapeutics Stock Up 4.3 %

Shares of NASDAQ:AVTX opened at $9.69 on Wednesday. The company has a 50-day moving average price of $9.19 and a 200 day moving average price of $11.43. Avalo Therapeutics has a 12 month low of $3.95 and a 12 month high of $42.34.

Avalo Therapeutics (NASDAQ:AVTX) last announced its earnings results on Monday, August 12th. The company reported ($14.07) EPS for the quarter, missing analysts’ consensus estimates of ($6.70) by ($7.37). Research analysts expect that Avalo Therapeutics will post -7.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Avalo Therapeutics

Several institutional investors have recently made changes to their positions in AVTX. Affinity Asset Advisors LLC bought a new position in Avalo Therapeutics during the 1st quarter valued at about $218,000. Ikarian Capital LLC purchased a new stake in shares of Avalo Therapeutics in the first quarter worth approximately $1,015,000. Finally, Logos Global Management LP bought a new position in Avalo Therapeutics in the 2nd quarter valued at $6,722,000. Institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.